ArticleEuropean heart journal. Imaging methods and practice2026
Comparing the prognostic utility of late gadolinium enhancement burden and phenotype in patients with cardiac sarcoidosis; a prospective cohort study.
Article in European heart journal. Imaging methods and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01477359 (Cardiac Sarcoidosis Multi-Center Prospective Cohort Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cardiac Sarcoidosis Multi-Center Prospective Cohort Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiac sarcoidosis (CS) is associated with a significant risk of ventricular arrhythmias (VAs). Recently, late gadolinium enhancement (LGE) phenotypes have been described; the 'pathology-frequent' phenotype has been shown to be strongly associated with future VA risk. The aim of our study was to compare the relative predictability of quantitative LGE burden and LGE phenotype. Secondary aims were to contrast the reproducibility and speed of LGE burden quantification and LGE phenotyping. Methods and results: This is a two-centre sub-study of the Cardiac Sarcoidosis Multi-Center Prospective Cohort Study (CHASM-CS; NCT01477359). All patients underwent CMR at baseline. A total of 206 patients (112/206 (54.4%) with CS and 94/206 (45.6%) with extra-cardiac sarcoidosis) were included in the study. Pathology-frequent LGE phenotype occurred in 85/206 (41.3%) and 22/206 (10.7%) patients had sustained VA during a mean follow-up period of 5.1 ± 2.8 years. All events occurred in patients with a pathology-frequent phenotype. LGE phenotype and categorical LGE% had similar high discriminative accuracy in predicting future VA; however, only LGE phenotyping had 100% negative predictive value (NPV). Interobserver reproducibility of LGE phenotype was very high (Cohen's Conclusion: Our study confirms, for the first time in a fully prospective cohort, the prognostic importance of the pathology-frequent phenotype of LGE. This phenotype had 100% NPV, indicating the absence of VA events among patients without a pathology frequent phenotype. LGE phenotyping showed much higher interobserver reproducibility than LGE quantification and was five-fold faster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.